Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 72-year-old man comes to the clinic for a routine follow-up visit. He was recently diagnosed with highly symptomatic paroxysmal atrial fibrillation. Attempts to control his rhythm with metoprolol and flecainide were unsuccessful due to poor tolerance, and he was transitioned to amiodarone 4 weeks ago. His other medical conditions include hypertension and hyperlipidemia. His current medications are metoprolol, apixaban, atorvastatin, and amiodarone. The patient feels well and reports no further palpitations, shortness of breath, or muscle aches. His pulse is 62/min and regular, and blood pressure is 128/78 mm Hg. Physical examination reveals clear lungs, a regular cardiac rhythm, and no peripheral edema. Which of the following diagnostic tests are indicated for the routine periodic surveillance of this patient's new antiarrhythmic therapy? (Select all that apply)

  1. Serum thyroid-stimulating hormoneAnswer
  2. Serum aminotransferasesAnswer
  3. Chest radiographyAnswer
  4. D
    Prothrombin time and partial thromboplastin time
  5. E
    Serum creatine kinase

Answer

The correct tests for routine monitoring are serum thyroid-stimulating hormone, serum aminotransferases, and chest radiography.
The correct diagnostic tests are serum thyroid-stimulating hormone, serum aminotransferases, and chest radiography. Amiodarone is a highly effective, iodine-rich antiarrhythmic medication with a high volume of distribution and a long half-life. It is associated with significant, time-dependent toxicity in multiple organ systems. To detect these adverse effects early, mandatory routine surveillance is indicated even in asymptomatic patients. Specifically, thyroid-stimulating hormone (TSH) should be evaluated at baseline and every 3 to 6 months to detect hypo- or hyperthyroidism. Serum aminotransferases must be checked at baseline and every 6 months to monitor for hepatotoxicity. Finally, a baseline chest radiograph and annual follow-up imaging are required to screen for insidious pulmonary toxicity, such as chronic interstitial pneumonitis.

Step-by-Step Solution

1
Identify the primary medication of concern and its adverse effect profile.
The patient was recently started on amiodarone, a class III antiarrhythmic known for significant multi-organ toxicity.
Recognizing the drug's safety profile dictates the long-term surveillance strategy.
2
Determine the standard monitoring parameters recommended for this medication.
Guidelines mandate baseline and periodic monitoring of thyroid function (TSH every 3-6 months), hepatic function (aminotransferases every 6 months), and pulmonary status (annual chest radiography).
These organs are the most common sites of severe, potentially irreversible amiodarone toxicity.
3
Evaluate the patient's other medications for interactions that might require additional routine testing.
The patient takes apixaban and atorvastatin. While amiodarone interacts with atorvastatin, asymptomatic patients do not require routine creatine kinase screening. Apixaban does not require coagulation monitoring.
Ruling out unnecessary tests avoids over-investigation and misinterpretation of the coagulation cascade and pharmacokinetic interactions.

Key Concept

Routine monitoring for patients on amiodarone therapy requires periodic evaluation of thyroid function (TSH), hepatic function (aminotransferases), and pulmonary status (chest radiography) due to the drug's multi-organ toxicity profile.
Estimated Time:1m 30s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic